Company Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.
The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells.
In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies.
The company was incorporated in 2017 and is headquartered in La Jolla, California.
| Country | United States |
| IPO Date | Jun 11, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Dr. David Alan Campbell Ph.D. |
Contact Details
Address: 11099 North Torrey Pines Road La Jolla, California United States | |
| Website | https://www.januxrx.com |
Stock Details
| Ticker Symbol | JANX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001817713 |
| CUSIP Number | 47103J105 |
| ISIN Number | US47103J1051 |
| Employer ID | 82-2289112 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Alan Campbell Ph.D. | President, Chief Executive Officer & Director |
| Andy Hollman Meyer | Chief Business Officer |
| Byron Robinson J.D., Ph.D. | Chief Strategy Officer |
| Charles M. Winter | Chief Technical Officer |
| Dr. Tommy Diraimondo Ph.D. | Chief Scientific Officer |
| James Pennington | General Counsel |
| Maria Dobek | Principal Accounting Officer & Vice President of Accounting |
| Matt Whitmire | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 05, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 424B5 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 424B5 | Filing |
| Dec 02, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |